Over a year annualised (CAGR), under a year absolute. Computed from AMFI's published
NAV history for this scheme.
Risk
Volatility
Sharpe
Sortino
Beta
Alpha
Max fall
R²
This scheme
15.3%
0.96
1.70
0.67
10.87%
-21.4%
44.11
Nifty 500 benchmark
15.2%
0.39
0.58
—
—
-37.3%
—
Risk-free rate 6.5%. Beta, alpha and R² are regressed on the
36 months this scheme and its benchmark share.
Growth of ₹100 since launch
Drawdown from peak (%)
Every one-year period it has lived through
Windows
Worst
Median
Best
Periods that lost money
1,516
-16.9%
16.4%
69.8%
22%
Every one-year holding period in this scheme's history, not just the last one — the
spread a real investor would have met depending only on when they started.
How it behaves against its benchmark
Up capture
Down capture
Correlation
Tracking error
Information ratio
Treynor
104%
52%
0.66
12.5%
0.71
22.20
Up capture is how much of the benchmark's gain this scheme kept in the months the
benchmark rose; down capture, how much of its fall it took. Below 100 on the down side and above it
on the up side is the combination every fund is trying for and few reach.
Measured over the 36 months this scheme and
Nifty 500 share.
Aditya Birla Sun Life Pharma and Healthcare Fund
Regular Plan · Growth
Allocation
By asset
Equity
97.94%
Cash & Equivalents
2.06%
By market cap
Large Cap
32.94%
Mid Cap
30.64%
Small Cap
31.74%
Unclassified
2.61%
Concentration
Number of stocks
39
Top 5 stocks
35.22%
Top 10 stocks
54.43%
Top 20 stocks
78.19%
Lines in the filing
41
Largest holding
9.28%
Largest sector
Pharmaceuticals & Biotechnology 74.91%
Effective stocks
23.9
Sectors held
4
Cash
2.06%
Effective stocks is what the concentration works out to: a fund holding
39 names but most of its money in a few
behaves like a fund of 24. Cash includes repo and TREPS, which
every fund parks money in overnight.
Sector split
Pharmaceuticals & Biotechnology
74.91%
Healthcare Services
21.61%
Cash & Equivalents
2.06%
Insurance
0.73%
Chemicals & Petrochemicals
0.69%
Aditya Birla Sun Life Pharma and Healthcare Fund
Regular Plan · Growth · holdings
Top 30 holdings
#
Company
Sector
Shares held
Value ₹ cr
% of fund
1
Torrent Pharmaceuticals Ltd.
Pharmaceuticals & Biotechnology
208,262
100
9.28%
2
Sun Pharmaceutical Industries Ltd.
Pharmaceuticals & Biotechnology
510,815
93
8.61%
3
Apollo Hospitals Enterprise Ltd.
Healthcare Services
84,936
69
6.44%
4
Cipla Ltd.
Pharmaceuticals & Biotechnology
510,452
69
6.38%
5
Aurobindo Pharma Ltd.
Pharmaceuticals & Biotechnology
291,254
49
4.52%
6
Sai Life Sciences Ltd.
Pharmaceuticals & Biotechnology
317,245
48
4.49%
7
Ajanta Pharma Ltd.
Pharmaceuticals & Biotechnology
129,312
47
4.35%
8
Mankind Pharma Ltd.
Pharmaceuticals & Biotechnology
155,574
39
3.62%
9
Dr. Lal Path labs Ltd.
Healthcare Services
190,095
38
3.51%
10
Abbott India Ltd.
Pharmaceuticals & Biotechnology
12,933
35
3.26%
11
Emcure Pharmaceuticals Ltd.
Pharmaceuticals & Biotechnology
177,757
35
3.21%
12
Lupin Ltd.
Pharmaceuticals & Biotechnology
156,214
32
2.94%
13
TREPS
Unclassified
—
31
2.92%
14
IPCA Laboratories Ltd.
Pharmaceuticals & Biotechnology
151,554
29
2.71%
15
Gland Pharma Ltd.
Pharmaceuticals & Biotechnology
100,517
29
2.70%
16
Fortis Healthcare Ltd.
Healthcare Services
339,011
26
2.42%
17
Corona Remedies Ltd.
Pharmaceuticals & Biotechnology
116,970
24
2.27%
18
Divi's Laboratories Ltd.
Pharmaceuticals & Biotechnology
26,000
24
2.24%
19
Procter & Gamble Health Ltd.
Pharmaceuticals & Biotechnology
35,195
20
1.82%
20
Thyrocare Technologies Ltd.
Healthcare Services
354,579
19
1.76%
21
Alkem Laboratories Ltd.
Pharmaceuticals & Biotechnology
35,039
18
1.68%
22
Jupiter Life Line Hospitals Ltd.
Healthcare Services
657,040
17
1.55%
23
Metropolis Healthcare Ltd.
Healthcare Services
293,640
16
1.48%
24
Biocon Ltd.
Pharmaceuticals & Biotechnology
422,052
16
1.45%
25
Shilpa Medicare Ltd.
Pharmaceuticals & Biotechnology
146,964
15
1.43%
26
Piramal Pharma Ltd.
Pharmaceuticals & Biotechnology
638,000
13
1.22%
27
Dr. Reddy's Laboratories Ltd.
Pharmaceuticals & Biotechnology
98,975
12
1.13%
28
Anthem Biosciences Ltd.
Pharmaceuticals & Biotechnology
141,684
12
1.13%
29
Sanofi Consumer Healthcare India Ltd.
Pharmaceuticals & Biotechnology
31,557
12
1.11%
30
Suraksha Diagnostic Ltd.
Healthcare Services
334,736
12
1.10%
Aditya Birla Sun Life Pharma and Healthcare Fund
Regular Plan · Growth · where the money sits
What the manager did last month
Between the filings of 30 Jun 2026 and 31 Jul 2026.
A position grows because the manager bought or because the price rose; only the share count separates them.
Bought
Sold
New positions
Sold out of
Price move of holdings
₹85 cr
₹26 cr
2
2
+4.42%
Stock
Shares traded
Shares
Price
Value ₹ cr
New position
Jupiter Life Line Hospitals Ltd.
657,040
entered
—
21.8
Manipal Health Enterprises Ltd A
162,425
entered
—
9.6
Added to
Torrent Pharmaceuticals Ltd.
105,816
+103.3%
+10.9%
54.2
Cipla Ltd.
130,000
+64.3%
+0.5%
19.2
Dr. Lal Path labs Ltd.
22,000
+22.5%
+15.7%
4.2
Sai Life Sciences Ltd.
30,737
+10.7%
+6.6%
4.0
Biocon Ltd.
45,564
+16.8%
+1.8%
1.9
Metropolis Healthcare Ltd.
25,000
+9.3%
+7.8%
1.5
Trimmed
Sun Pharmaceutical Industries Ltd.
130,000
-19.8%
+6.9%
25.9
Sold out of
J.B. Chemicals & Pharmaceuticals Limited
207,484
exited
—
47.6
Jupiter Life Line Hospitals Ltd
131,408
exited
—
18.7
Not equity
Previous filing
This filing
Change
Cash, repo and TREPS
₹0 cr
₹0 cr
+₹0 cr
The list above is stocks and fund units. Treasury bills, repo and money-market
lines roll over every month by design — they are not decisions, so they are totalled here rather
than listed as activity.
A ₹10,000 monthly SIP over five years
Invested
Value
Gain
XIRR
₹600,000
₹963,573
₹363,573
19.04%
XIRR, not CAGR — a SIP's money arrives over sixty months, so each instalment has
been invested for a different length of time.
Not investment advice. InvestVerdict is not a SEBI-registered Investment
Adviser or Research Analyst. Every figure is computed from AMFI's published NAV history and the
portfolio the AMC filed with AMFI; none of it is a recommendation to buy, hold or sell. Past
returns do not predict future ones. Generated 31 Oct 2026.
